RxDoctor Payments Data

Kanupriya Mathur, MD

Internal Medicine · Jacksonville, FLNPI 1679885248

Payments from drug & device makers

$983in general payments, 2019–2025

Across 34 payments — averaging $28.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$268
  • Merck$126
  • Lilly USA, LLC$124
  • Dexcom, Inc.$108
  • Novartis$79
  • Jazz Pharmaceuticals Inc.$48
  • plus $231 from 6 others

What the payments were for

  • Food & beverage$97099%
  • Education$141%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$983 in reported general payments places this provider in the 65th percentile of 8,530 internal medicine providers in Florida.

See all internal medicine providers in Florida

Medicare billing

Part B allowed, 2024
$180,144
Medicare patients
318
Services billed
2,597

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide113$177,412
EliquisApixaban154$127,370
MounjaroTirzepatide36$69,558
Tresiba Flextouch U-200Insulin Degludec22$52,005
JardianceEmpagliflozin33$36,122
FarxigaDapagliflozin Propanediol30$28,830
XareltoRivaroxaban32$26,252
JanuviaSitagliptin Phosphate20$19,239
MyrbetriqMirabegron12$14,924
Breztri AerosphereBudesonide/Glycopyr/Formoterol18$11,672
Humalog Kwikpen U-100Insulin Lispro23$5,628
Levothyroxine Sodium370$4,517
Lantus SolostarInsulin Glargine,hum.Rec.Anlog30$4,493
SymbicortBudesonide/Formoterol Fumarate19$4,145
Gabapentin224$3,938

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$35$177,412113 claims
Lilly USA, LLCMounjaro$124$69,55836 claims
Boehringer IngelheimJardiance$40$36,12233 claims
MerckJanuvia$126$19,23920 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 8,530 internal medicine providers in Florida.

Other internal medicine in Jacksonville

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →